- A new drug application is expected to be submitted to the FDA in 2025.
“We believe the unique multifaceted mechanism of action of brilaroxazine, a serotonin-dopamine signaling modulator, has potential to improve additional key disease drivers like neuroinflammation,” Laxminarayan Bhat, PhD,** founder, president and CEO of Reviva Pharmaceuticas, said in the release.
The trial of 412 patients, called RECOVER, found that a daily dose of brilaroxazine yielded a 10.1-point greater reduction in total Positive and Negative Syndrome Scale (PANSS) score at 4 weeks compared with placebo, according to the release.
